Muscle & growth hormone
CJC-1295 (No DAC): published research
Also known as Modified GRF (1-29)
A modified form of the first 29 amino acids of GHRH, with four amino-acid swaps that slow its breakdown. Without the 'DAC' attachment it acts briefly, in pulses, like the body's own signal. Studies measure growth-hormone and IGF-1 release.
Evidence at a glance
4 studies 2005–2006
- 2 Human trial
- 2 Animal study
What researchers look at
- GHRH signalling
- Growth-hormone pulses
- IGF-1 levels
- Pituitary
What is still unknown
Published human trials used the longer-acting DAC version; direct human data on this form are limited.
Studies in people
2- Human trial
Using CJC-1295 with DAC (no published study used the no-DAC form): in two randomised placebo-controlled trials in healthy adults, it produced sustained, dose-dependent increases in GH and IGF-I.
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism. 2006. PMID 16352683
- Human trial
Using CJC-1295 with DAC: in healthy young men, a single injection raised baseline and average GH and IGF-I levels while the natural pulse pattern of GH was preserved.
Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology and Metabolism. 2006. PMID 17018654
Animal studies
2- Animal study
Using CJC-1295 with DAC: in mice lacking natural GHRH, repeated treatment maintained normal body weight, length and body composition and increased pituitary GH production.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism. 2006. PMID 16822960
- Animal study
Using CJC-1295 with DAC: in rats and cultured rat pituitary cells, this albumin-binding modified GRF(1-29) stimulated GH release and stayed in the blood for more than 72 hours.
Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669
Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.